AbbVie Dividends

AbbVie Dividend History

Last updated: November 15, 2026

This article was generated with AI assistance.

Yes, AbbVie is a Dividend Aristocrat. AbbVie Inc. (NYSE: ABBV) is a member of the S&P 500 and of the S&P 500 Dividend Aristocrats, the group of S&P 500 companies that have increased their regular dividends every year for at least 25 consecutive years. AbbVie has been in that index since January 2013, the month it became an independent company. It qualifies because S&P counts Abbott Laboratories’ pre-2013 dividend-increase history together with AbbVie’s own record since the spin-off, not because AbbVie has yet completed 25 standalone years of increases.

A long payment record is useful context. It is not a guarantee of future increases or of investment performance. Companies can reduce, suspend, or eliminate their dividends.

About AbbVie

AbbVie is a global, diversified research-based biopharmaceutical company. Its 2025 Form 10-K says it has leadership positions across immunology, neuroscience, oncology, and aesthetics, and that it operates as a single global business segment dedicated to the research and development, manufacturing, commercialization, and sale of innovative medicines and therapies.

AbbVie was formed on January 1, 2013, as a spin-off from Abbott Laboratories. In that separation, Abbott retained a portfolio of diversified health care products, and AbbVie became the independent biopharmaceutical company. AbbVie is a Delaware corporation. Its principal executive offices are at 1 North Waukegan Road, North Chicago, Illinois. The common stock trades on the New York Stock Exchange under the ticker ABBV. Robert A. Michael is chairman and chief executive officer.

On May 8, 2020, AbbVie completed its acquisition of Allergan, which added aesthetics products, including Botox, and other specialty medicines. In its October 30, 2026, third-quarter results, the company also said it had completed the acquisition of Apogee Therapeutics.

For the year ended December 31, 2025, AbbVie reported net revenues of $61.2 billion, up 8.6% from $56.3 billion in 2024. It employed approximately 57,000 people in over 70 countries as of December 31, 2025. Those figures replace the 25,000 employees and “over 170 countries” description on the prior version of this page.

Immunology remains the center of the portfolio, but the mix has changed since this page was last updated. In 2025, worldwide net revenues from Skyrizi were $17.6 billion, and Rinvoq contributed $8.3 billion. Humira, once the company’s largest product, had worldwide net revenues of $4.5 billion, down about 50% from $9.0 billion in 2024 and $14.4 billion in 2023, as biosimilar competition continued. Other important products include Vraylar and Botox Therapeutic.

How AbbVie became a Dividend Aristocrat

AbbVie has increased its dividend every year since it became a public company in 2013, but that standalone streak is still well short of the 25 years required for S&P 500 Dividend Aristocrat status. The reason AbbVie is nonetheless an Aristocrat is the way S&P treated the Abbott spin-off.

On January 21, 2013, AbbVie announced that it had been named to the S&P 500 Dividend Aristocrat Index “as a result of the Index’s change in its treatment of spin-off companies.” The same day, Abbott said it had increased its dividend for 40 consecutive years and that AbbVie, which had become independent on January 1, 2013, “was also named to both lists based on the history of the combined companies’ dividend record.” In other words, S&P carried Abbott’s pre-2013 increase history over to AbbVie, and AbbVie has kept the annual-increase policy going since then. Abbott remains a separate Dividend Aristocrat with its own continuing record.

AbbVie’s dividend history

AbbVie usually announces its annual dividend increase in late October, and the higher rate typically begins with the February payment of the following year, with the stock going ex-dividend in January. That calendar still matches the description in the older version of this post.

On October 30, 2026, AbbVie announced a 5.2% increase in its quarterly cash dividend, from $1.73 per share to $1.82 per share, beginning with the dividend payable February 16, 2027, to shareholders of record on January 15, 2027. Dividends payable through the November 16, 2026, payment remain $1.73. The company said that, since its inception in 2013, it has increased its quarterly dividend by 355%. That percentage is the increase from an inaugural $0.40 quarterly rate to $1.82.

From the $1.41 quarterly rate in effect after the increase announced on October 29, 2021, and later declared on February 17, 2022, to the new $1.82 rate, the dividend has compounded at about 5.2% a year. From the $0.64 quarterly rate announced on October 28, 2016, and first payable February 15, 2017, to $1.82, the 10-year compounded rate is about 11.0%. Those figures replace the outdated “17.5% over the last 5 years” growth rate on the prior version of this page.

AbbVie’s stock-split history

AbbVie has not split its stock since the January 1, 2013, separation from Abbott.

Risks and other considerations

AbbVie’s results depend on a concentrated set of patented medicines, the timing of new approvals, and competition from biosimilars and other therapies. Humira’s sharp revenue decline after the loss of exclusivity shows how quickly a flagship product can shrink. The dividend’s future support will depend on whether growth in Skyrizi, Rinvoq, and the rest of the portfolio, including products added through Allergan and later acquisitions, more than offsets that loss and funds a large R&D and commercial organization. Pricing, reimbursement, and litigation, including product-liability and intellectual-property disputes, are ongoing risks in the biopharmaceutical industry. A long, inherited dividend record does not remove those risks.

FAQ

Is AbbVie a Dividend Aristocrat? Yes. AbbVie is a current member of the S&P 500 Dividend Aristocrats. It was added in January 2013 because S&P counted Abbott’s pre-2013 dividend-increase history, together with AbbVie’s policy of continuing annual increases after the spin-off. AbbVie’s own standalone increase record since 2013 is still shorter than 25 years.

What is AbbVie’s current dividend? The latest declared increase takes the quarterly rate from $1.73 to $1.82, a 5.2% increase, beginning with the payment on February 16, 2027. Payments through November 16, 2026, remain $1.73.

When was AbbVie spun off from Abbott? AbbVie became an independent company on January 1, 2013.

Did AbbVie acquire Allergan? Yes. The Allergan acquisition closed on May 8, 2020.

Has AbbVie split its stock? No. There has been no split since the 2013 separation.

Helpful links

Disclosure: As of the date of this article, I do not currently own shares of ABBV, but that may change at any time.

Sources